3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
12
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
4
Myeloid
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Genitourinary
1
Gastrointestinal
1
Conditions
Polycythemia Vera
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Azacitidine
68
nilotinib
50
Imatinib Mesylate
50
ruxolitinib
42
Dasatinib
25
venetoclax
22
Decitabine
20
bosutinib
18
asciminib
17
Cytarabine
15
ponatinib
10
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
9
fludarabine
8
Hydroxyurea
8
navitoclax
6
ON 01910
6
sabatolimab
5
pevonedistat
5
mocetinostat
5
luspatercept
5
itacitinib
5
imetelstat
5
givinostat hydrochloride
5
givinostat
5
fludarabine phosphate
5
avapritinib
5
Mycophenolic Acid
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
peginterferon alfa-2b
×
Myeloid
×
Clear all
NCT03547154
2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
344 enrolled
11 charts
NCT01949805
2016-11-28
PROUD-PV
AOP Orphan Pharmaceuticals AG
Phase 3
Completed
257 enrolled